2026 China Healthcare Financing Trends: Dual Drivers of Investment and Overseas Expansion

China’s healthcare industry in 2026 is entering a new phase of value realization.

The primary financing market is gradually recovering, innovative drug BD remains active, and healthcare companies are accelerating their international expansion. The relationship between capital and industry is undergoing new changes.

I. The Financing Market is Shifting from Quantity to Quality

In the past few years, healthcare investment has undergone a significant cyclical adjustment.

Investment institutions are no longer solely focused on popular tracks, but are paying more attention to:

• Clinical data;
• Product commercialization capabilities;
• Technological barriers;
• Team execution capabilities;
• Internationalization potential.

For startups, financing is no longer just about solving cash flow problems, but is part of the company’s strategic planning.

II. BD is Becoming an Important Source of Capital

For innovative drug companies, license-out and other BD transactions are becoming an important source of funding in addition to financing.

This means companies need to re-evaluate the value of their assets.

What a company sells is not necessarily just a product, but could also be:

• A technology platform;
• Clinical development capabilities;
• A product pipeline;
• Global development rights;
• Regional commercialization rights.

Therefore, BD transactions are becoming increasingly aligned with a company’s overall strategy.

III. Medical Device Companies are Placing More Emphasis on Commercialization

For medical device companies, product approval is just the beginning of commercialization.

The capital market is increasingly focused on:

• Whether the product has truly entered clinical practice;
• Hospital installation and usage rates;
• Reimbursement pathways;
• The medical insurance and payment environment;
• The speed of market expansion;
• Overseas market potential.

Companies need to move from “product value” to “commercial value.”

IV. Overseas Expansion is Becoming a Long-Term Strategy

The internationalization of Chinese healthcare companies has gradually expanded from simple product exports to:

Technology export, capital export, cooperative export, and internationalization of the industrial chain.

For companies with technological barriers and clinical value, overseas markets may become an important source of future growth.

T-Capital’s View

We believe that the core keyword of the future healthcare capital market will gradually shift from “financing” to “value realization.”

For companies, the most important question is not:

“Can we get financing now?”

But rather:

“How should the company achieve the next stage of value growth through capital, transactions, and industrial resources?”

This is also the core logic behind T-Capital’s long-term focus on the development of healthcare companies.